Lv5
980 积分 2021-11-28 加入
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors
12小时前
已完结
TET2–STAT3–CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition
4个月前
已完结
Specimen Considerations in Molecular Oncology Testing
6个月前
已完结
De Novo MET Amplification in Chinese Patients With Non–Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study
6个月前
已完结
Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation
6个月前
已完结
Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer
6个月前
已完结
MET alterations in NSCLC—Current Perspectives and Future Challenges
6个月前
已完结
Crizotinib in Patients With MET-Amplified NSCLC
6个月前
已完结
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
6个月前
已完结
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer
6个月前
已完结
皖公网安备34019202002308
